Wuhan Keqian Biology Co Ltd

KQ Bio announced that after review by the Ministry of Agriculture and Rural Affairs, the company's feline rhinotracheitis, calicivirus disease, and panleukopenia triple inactivated vaccine has been approved as a new veterinary drug, with a New Veterinary Drug Registration Certificate issued. The registration classification is Category III, with a monitoring period of three years. The vaccine is used to prevent feline rhinotracheitis, feline calicivirus disease, and feline panleukopenia. The immunity onset period is 21 days after the second immunization, and the immunity duration is 12 months. The development units include Huazhong Agricultural University, Wuhan KQ Bio, Yunnan Biopharmaceutical, and Huapai Biotechnology Group. The company stated that the approval of this product will further enrich its product portfolio, promote business diversification, and help enhance market competitiveness. Before the product can be marketed and sold, it still needs to obtain a product approval number. The timing of obtaining it and subsequent production and sales are uncertain, and investors should be aware of the risks.

Yuanjie Technology announced plans to invest approximately 4.268 billion yuan in the construction of the Yuanjie Semiconductor Technology Industrial Park project. This is one of the major announcements this evening. In addition, New Beiyang won the bid for the mail processing center equipment procurement project. Keqian Bio plans to sign a cooperative research and development agreement with Huazhong Agricultural University. Baicheng Pharma's sitagliptin metformin extended-release tablets were selected in the national centralized drug procurement. Shuangliang Energy won the bid for a 339 million yuan air-cooling EPC project. Runbang Heavy Industry's subsidiary signed a sales contract for six live fish transport vessels with a total value of approximately 2.8 billion to 3.3 billion yuan. Holike's wholly-owned subsidiary plans to invest 50 million yuan to subscribe for fund shares. HNA Holding's controlling subsidiary plans to sell 80 percent equity in HNA Resources and Environment. Dongyangguang's controlling subsidiary plans to increase capital and expand shares to introduce investors. Yaben Chemical plans to raise no more than 841 million yuan through a private placement for a pilot project producing 35 tons of high-end pharmaceutical intermediates annually. Qiangrui Technology plans to raise no more than 1.05 billion yuan through a private placement for a high-end semiconductor equipment precision components production and manufacturing project.

KQ Bio-Tech announced that on July 30, 2026, it received two new veterinary drug registration certificates issued by the Ministry of Agriculture and Rural Affairs. One is a combined inactivated vaccine against porcine epidemic diarrhea and porcine rotavirus disease (G9 type), using strains HB17 and JS01, for preventing diarrhea in pigs caused by PEDV and PoRV G9 infection. The immunity period is three months, addressing the current situation where co-infection of PEDV and PoRV is common in clinical settings and G9 type has become the dominant circulating strain. The other is a quadrivalent inactivated vaccine against Newcastle disease, avian influenza (H9 subtype), infectious bursal disease, and fowl adenovirus disease (group I, serotype 4), using strains La Sota, HB01, rVP2, and rFiber2, for preventing four avian diseases. This targets the prevalence of very virulent strains of infectious bursal disease and the endemic circulation of fowl adenovirus. Both products are classified as Class III new veterinary drugs with a three-year monitoring period.